Address: 2 Eastman Way, Stevenage, Hertfordshire, SG1 4SZ,United Kingdom
Tel: +44 (0) 1438 737630
Web: http://www.arrowgenerics.co.uk/
Watson Pharmaceuticals Inc. (NYSE: WPI) entered the UK market in 2009 when it acquired the Arrow Group. Watson is a leading integrated global pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic, brand and biologic pharmaceutical products. Watson is among the top five pharmaceutical companies in the United States, based on total prescriptions, and the fourth largest generics pharmaceutical company in the world. The company has commercial operations in many of the world’s established and emerging international markets. Watson’s largest commercial market is the United States, followed by key international markets including France, UK, Canada and Brazil.
Watson has three businesses in the UK.
Arrow No 7 is the base for the Group’s European headquarters in London.
Arrow Generics UK covers a wide range of therapeutic areas including standard and modified release presentations of tablets and capsules. The range does not stop there however and includes specialised presentations of creams, ointments, drops, suspensions, syrups, solutions and suspensions for nebulisation.
With a large emphasis within the Group being concentrated on the development of future patent expiring molecules, Arrow in the UK has benefited from the launch of numerous products on day ‘one’ following patent expiry. This continues to be the key strategy for the management team, many of whom have extensive experience of the generics industry.
Eden Biodesign is designated as Watson’s Centre of Excellence for Biologics, delivering process and product development; cGMP manufacturing of biologics and quality/regulatory expertise from a custom-designed facility located in Liverpool, UK.
With well over a decade of experience in producing a wide range of complex biopharmaceuticals, Eden Biodesign provides Watson with a strong foundation for establishing a leadership position in global biologics.
Eden Biodesign is currently developing biosimilar versions of complex biopharmaceuticals, such as recombinant Follicle Stimulating Hormone (rFSH) which was in-licensed in July 2010.
For more information on products and services please visit http://www.arrowgenerics.co.uk or http://www.edenbiodesign.com/.
Following the acquisition of Arrow Generics by Watson in December 2009, what complementarities and synergies were generated from the transaction and where do you stand today with the integration? Since…
The UK government has decided to go ahead with a much-debated increase in the revenue clawback rate —from 24.4 percent to 27.5 percent— for drugmakers subject to its Statutory Scheme…
Dr Matt Linley, senior director for analytics and forecasting at predictive health analytics firm Airfinity, looks ahead to a potentially game-changing year in the fight against respiratory synctial virus (RSV),…
A roundup of the latest UK healthcare, pharma and biotech news including AbbVie and Lilly’s departure from the country’s voluntary medicines pricing agreement, Moderna’s expanded footprint, UK biotech’s 2022 funding…
What digital skills do pharma leaders need in order to drive transformation, deliver success at scale in the business, and prepare for next-gen customer engagement? Sarah Gilchriest explores the critical…
Bernard Ross, a serial entrepreneur with more than 20 years’ senior experience at private and public board level across multiple industries, looks ahead to 2023 and highlights five key trends…
After an almost 20-year career in Big Pharma culminating in a role as president of AstraZeneca UK, Lisa Anson took the leap into the biotech world to lead what at…
Pricing and market access have become increasingly hot topics in recent years, as healthcare systems across the world attempt to balance their own financial sustainability with securing the latest medical…
National Health Service (NHS) England CEO Amanda Pritchard has raised concerns about the state of British healthcare in recent weeks and months, proclaiming that the NHS is in a worse…
With the brief tenure of Liz Truss as Prime Minister already drawing to a close, the UK faces yet another new leader as the country attempts to extricate itself from…
“Life sciences are at the heart of my vision to build a country fit for the future,” tweeted new UK Prime Minister Liz Truss last month. Now installed as leader…
US biotech Moderna – producer of a messenger RNA (mRNA) COVID-19 vaccine that has found its way into 75 million arms in the US alone and generated USD 12 billion…
After several scandals that revealed longstanding deficiencies and a continual churn of executive staff, a recent independent review of leadership in the National Health Service (NHS) has uncovered a lack…
See our Cookie Privacy Policy Here
